{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:33Z","timestamp":1788952353030,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10147-020-01810-x","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T12:02:22Z","timestamp":1603368142000},"page":"370-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden"],"prefix":"10.1007","volume":"26","author":[{"given":"Hirosumi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-5827","authenticated-orcid":false,"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ueyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichinosuke","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"3","key":"1810_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M","volume":"41","author":"JB Dupont Jr","year":"1978","unstructured":"Dupont JB Jr, Lee JR, Burton GR et al (1978) Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 41(3):941\u2013947","journal-title":"Cancer"},{"issue":"9742","key":"1810_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"1","key":"1810_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36\u201346","journal-title":"N Engl J Med"},{"issue":"4","key":"1810_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB et al (2009) Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20(4):666\u2013673","journal-title":"Ann Oncol"},{"issue":"3","key":"1810_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221","journal-title":"Lancet Oncol"},{"issue":"11","key":"1810_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224\u20131235","journal-title":"Lancet Oncol"},{"issue":"1","key":"1810_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000290955","volume":"78","author":"J Kitayama","year":"2010","unstructured":"Kitayama J, Ishigami H, Kaisaki S et al (2010) Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology 78(1):40\u201346","journal-title":"Oncology"},{"issue":"4","key":"1810_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s10120-001-8012-x","volume":"4","author":"M Tahara","year":"2001","unstructured":"Tahara M, Ohtsu A, Boku N et al (2001) Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 4(4):212\u2013218","journal-title":"Gastric Cancer"},{"issue":"4","key":"1810_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N et al (2020) Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer 23(4):677\u2013688","journal-title":"Gastric Cancer"},{"issue":"5","key":"1810_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","volume":"3","author":"MA Shah","year":"2017","unstructured":"Shah MA, Bang YJ, Lordick F et al (2017) Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized cinical trial. JAMA Oncol 3(5):620\u2013627","journal-title":"JAMA Oncol"},{"issue":"12","key":"1810_CR11","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/annonc\/mdw423","volume":"27","author":"HH Yoon","year":"2016","unstructured":"Yoon HH, Bendell JC, Braiteh FS et al (2016) Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 27(12):2196\u20132203","journal-title":"Ann Oncol"},{"issue":"10111","key":"1810_CR12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390(10111):2461\u20132471","journal-title":"The Lancet"},{"issue":"1","key":"1810_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","volume":"18","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Kawazoe A, Shimada K et al (2018) A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 18(1):120","journal-title":"BMC Cancer"},{"issue":"1","key":"1810_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 6(1):74","journal-title":"J Immunother Cancer"},{"key":"1810_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","volume":"18","author":"MR Cassidy","year":"2017","unstructured":"Cassidy MR, Wolchok RE, Zheng J et al (2017) Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine 18:56\u201361","journal-title":"EBioMedicine"},{"issue":"4","key":"1810_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J et al (2016) Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27(4):732\u2013738","journal-title":"Ann Oncol"},{"issue":"3","key":"1810_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cllc.2018.04.021","volume":"20","author":"T Fukui","year":"2019","unstructured":"Fukui T, Okuma Y, Nakahara Y et al (2019) Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer 20(3):208\u2013214","journal-title":"Clin Lung Cancer"},{"key":"1810_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Oncol Targets Ther 11:955\u2013965","journal-title":"Oncol Targets Ther"},{"key":"1810_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.12.014","volume":"140","author":"E Baldini","year":"2020","unstructured":"Baldini E, Lunghi A, Cortesi E et al (2020) Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program. Lung Cancer 140:59\u201364","journal-title":"Lung Cancer"},{"issue":"10","key":"1810_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","volume":"22","author":"J Judd","year":"2017","unstructured":"Judd J, Zibelman M, Handorf E et al (2017) Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. Oncologist 22(10):1232\u20131237","journal-title":"Oncologist"},{"issue":"1","key":"1810_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","volume":"19","author":"K Masuda","year":"2019","unstructured":"Masuda K, Shoji H, Nagashima K et al (2019) Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19(1):974","journal-title":"BMC Cancer"},{"key":"1810_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2020","unstructured":"Schvartsman G, Peng SA, Bis G et al (2020) Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-smallcell lung cancer. Lung Cancer 112:90\u201395","journal-title":"Lung Cancer"},{"issue":"4","key":"1810_CR23","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s13277-013-1426-3","volume":"35","author":"N Fang","year":"2014","unstructured":"Fang N, Zhang HQ, He B et al (2014) Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites. Tumour Biol 35(4):3261\u20133268","journal-title":"Tumour Biol"},{"issue":"3","key":"1810_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3748\/wjg.v22.i3.1190","volume":"22","author":"B Lim","year":"2016","unstructured":"Lim B, Kim JH, Kim M et al (2016) Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol 22(3):1190\u20131201","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1810_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol 38(1):1\u201310","journal-title":"J Clin Oncol"},{"issue":"3","key":"1810_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1440-1746.2010.06487.x","volume":"26","author":"H Kim","year":"2011","unstructured":"Kim H, An JY, Noh SH et al (2011) High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol 26(3):585\u2013592","journal-title":"J Gastroenterol Hepatol"},{"issue":"7517","key":"1810_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202\u2013209","journal-title":"Nature"},{"issue":"26","key":"1810_CR28","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520","journal-title":"N Engl J Med"},{"key":"1810_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1\u20137","journal-title":"Lung Cancer"},{"issue":"77","key":"1810_CR30","doi-asserted-by":"publisher","first-page":"34520","DOI":"10.18632\/oncotarget.26145","volume":"9","author":"T Ogata","year":"2018","unstructured":"Ogata T, Satake H, Ogata M et al (2018) Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget 9(77):34520\u201334527","journal-title":"Oncotarget"},{"issue":"2","key":"1810_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00280-019-04023-w","volume":"85","author":"Y Ota","year":"2020","unstructured":"Ota Y, Takahari D, Suzuki T et al (2020) Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol 85(2):265\u2013272","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01810-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:17:47Z","timestamp":1659061067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01810-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01810-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HS, TY, AS, SU, YY and TM declare that they have no conflict of interest. IH reports grants and personal fees from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., personal fees from Eli Lilly Japan K.K., Asahi Kasei Pharma Corp., and grants from Takeda Pharmaceutical Co., Ltd., unrelated to the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}